Tempest to Participate in Panel Discussion at 2022 William Blair Biotech Focus Conference
July 07 2022 - 7:00AM
Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage
oncology company developing first-in-class¹ therapeutics that
combine both targeted and immune-mediated mechanisms, today
announced that Tom Dubensky, Ph.D., will participate in a panel
titled “Developing Therapies for the Next Immuno-Oncology Targets”
at the 2022 William Blair Biotech Focus Conference on Tuesday, July
12, 2022 at 4:10 p.m. ET.
About Tempest Therapeutics
Tempest Therapeutics is a clinical-stage
oncology company advancing small molecules that combine both
tumor-targeted and immune-mediated mechanisms with the potential to
treat a wide range of tumors. The company’s two novel clinical
programs are TPST-1120 and TPST-1495, antagonists of PPARα and
EP2/EP4, respectively. Both TPST-1120 and TPST-1495 are advancing
through clinical trials designed to study both agents as
monotherapies and in combination with other approved agents.
Tempest is also developing an orally-available inhibitor of TREX-1,
a DNA repair enzyme that controls activation of the cGAS/STING
pathway, an innate immune response pathway important for the
development of anti-tumor immunity. Tempest is headquartered in
South San Francisco. More information about Tempest can be found on
the company’s website at www.tempesttx.com.
Investor Contact:
Sylvia WheelerWheelhouse Life Science
Advisorsswheeler@wheelhouselsa.com
Media Contact:
Aljanae Reynolds Wheelhouse Life Science
Advisorsareynolds@tempesttx.com
__________________________
¹ If approved
Tempest Therpeutics (NASDAQ:TPST)
Historical Stock Chart
From Jul 2024 to Jul 2024
Tempest Therpeutics (NASDAQ:TPST)
Historical Stock Chart
From Jul 2023 to Jul 2024